HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Consumer Medical Device

House Members Propose Primatene Mist Inventory Clearance Sale

This article was originally published in The Tan Sheet

  • News

Executive Summary

The House Energy and Power Subcommittee July 18 will discuss draft legislation that would require EPA to allow sales of the remaining inventory of Armstrong Pharmaceutical’s CFC-propelled epinephrine inhalers, Primatene Mist.

You may also be interested in...



FDA Should Release Existing Supply Of Primatene Mist OTC Asthma Inhaler, Rep. Says

Lawmakers seek to restore the availability of Primatene Mist while the absence of an alternative OTC asthma remedy persists.

Primatene Mist Chances To Remain On Market Dwindle With Senate Vote

FDA Expectation For Replacement OTC Inhaler Remains Unfulfilled

The only inhalers to treat asthma available after Dec. 31 will be prescription products.

Table

View full table

Topics

Related Companies

Tags:
BioPharmaceutical Consumer Medical Device
Latest Headlines

Probiotics And Cold Remedies Boost Recordati In 2023

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches

See All
UsernamePublicRestriction

Register

RS124559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By